Clinical Trial Update: SCION: SABR and Checkpoint Inhibition of NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial (SCION) evaluating stereotactic ablative radiotherapy (SABR) with checkpoint inhibition for non-small cell lung cancer has been withdrawn. The w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer
• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Snippet

Sponsor: University of British Columbia | Conditions: Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: WITHDRAWN